CASI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CASI)

$3.98 0.13 (3.38 %)
(As of 01/19/2018 06:22 AM ET)
Previous Close$3.85
Today's Range$3.83 - $4.09
52-Week Range$0.91 - $4.84
Volume256,400 shs
Average Volume250,692 shs
Market Capitalization$250.51 million
P/E Ratio-26.53
Dividend YieldN/A
Beta1.08

About CASI Pharmaceuticals (NASDAQ:CASI)

CASI Pharmaceuticals logoCASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development. Its ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. Its Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate. Its ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. Its EVOMELA is an intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. Its pipeline also includes 2ME2 (2-methoxyestradial).

Receive CASI News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CASI
CUSIPN/A
Phone240-864-2600

Debt

Debt-to-Equity RatioN/A
Current Ratio7.36%
Quick Ratio7.36%

Price-To-Earnings

Trailing P/E Ratio-26.5315645623625
Forward P/E Ratio-30.62
P/E GrowthN/A

Sales & Book Value

Annual Sales$50,000.00
Price / Sales5,179.57
Cash FlowN/A
Price / CashN/A
Book Value$0.35 per share
Price / Book11.37

Profitability

Trailing EPS($0.15)
Net Income$-9,450,000.00
Net MarginsN/A
Return on Equity-46.26%
Return on Assets-33.35%

Miscellaneous

Employees27
Outstanding Shares65,070,000

CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) posted its earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.04) by $0.01. View CASI Pharmaceuticals' Earnings History.

When will CASI Pharmaceuticals make its next earnings announcement?

CASI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March, 29th 2018. View Earnings Estimates for CASI Pharmaceuticals.

Where is CASI Pharmaceuticals' stock going? Where will CASI Pharmaceuticals' stock price be in 2018?

2 analysts have issued 1-year price targets for CASI Pharmaceuticals' shares. Their predictions range from $4.00 to $5.00. On average, they anticipate CASI Pharmaceuticals' share price to reach $4.50 in the next twelve months. View Analyst Ratings for CASI Pharmaceuticals.

Who are some of CASI Pharmaceuticals' key competitors?

Who are CASI Pharmaceuticals' key executives?

CASI Pharmaceuticals' management team includes the folowing people:

  • Wei-Wu He Ph.D., Chairman of the Board (Age 50)
  • Ken K. Ren Ph.D., Chief Executive Officer, Director (Age 56)
  • Cynthia Wong Hu J.D., Chief Operating Officer, General Counsel, Secretary (Age 45)
  • Sara B. Capitelli CPA, Vice President - Finance, Principal Accounting Officer (Age 48)
  • Rong Chen M.D., Ph.D., Chief Medical Officer
  • Tak W. Mak Ph.D., Director (Age 69)
  • Rajesh C. Shrotriya M.D., Director (Age 73)
  • James Z. Huang, Independent Director (Age 50)
  • Franklin C. Salisbury Jr., Independent Director (Age 59)
  • Y. Alexander Wu Ph.D., Independent Director (Age 51)

How do I buy CASI Pharmaceuticals stock?

Shares of CASI Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CASI Pharmaceuticals' stock price today?

One share of CASI Pharmaceuticals stock can currently be purchased for approximately $3.98.

How big of a company is CASI Pharmaceuticals?

CASI Pharmaceuticals has a market capitalization of $250.51 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-9,450,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. CASI Pharmaceuticals employs 27 workers across the globe.

How can I contact CASI Pharmaceuticals?

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected]


MarketBeat Community Rating for CASI Pharmaceuticals (CASI)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  131
MarketBeat's community ratings are surveys of what our community members think about CASI Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

CASI Pharmaceuticals (NASDAQ:CASI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.50$3.00$3.00$4.00
Price Target Upside: 20.00% upside19.52% upside172.73% upside312.33% upside

CASI Pharmaceuticals (NASDAQ:CASI) Consensus Price Target History

Price Target History for CASI Pharmaceuticals (NASDAQ:CASI)

CASI Pharmaceuticals (NASDAQ:CASI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018HC WainwrightReiterated RatingBuy$5.00HighView Rating Details
11/14/2017Maxim GroupSet Price TargetBuy$4.00N/AView Rating Details
(Data available from 1/19/2016 forward)

Earnings

CASI Pharmaceuticals (NASDAQ:CASI) Earnings History and Estimates Chart

Earnings by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)

CASI Pharmaceuticals (NASDAQ CASI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/29/2018($0.03)N/AView Earnings Details
11/14/2017Q3 2017($0.04)($0.03)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.03)($0.04)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.04)($0.03)ViewN/AView Earnings Details
3/31/2017Q4 2016($0.07)($0.05)$0.50 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.08)($0.03)ViewN/AView Earnings Details
8/15/2016Q2($0.04)($0.08)ViewN/AView Earnings Details
5/13/2016Q1($0.05)($0.04)ViewN/AView Earnings Details
3/28/2016Q415($0.03)($0.05)$0.03 millionViewN/AView Earnings Details
11/13/2015Q315($0.07)($0.05)$0.10 millionViewN/AView Earnings Details
8/14/2015Q215($0.06)($0.06)$0.27 million$0.02 millionViewN/AView Earnings Details
5/15/2015Q1 2015($0.06)ViewN/AView Earnings Details
3/27/2015Q4 2014($0.05)ViewN/AView Earnings Details
11/14/2014Q314($0.07)ViewN/AView Earnings Details
8/14/2014Q214($0.06)ViewN/AView Earnings Details
5/15/2014Q114($0.05)($0.05)ViewN/AView Earnings Details
3/21/2014Q413($0.05)$0.67 millionViewN/AView Earnings Details
11/13/2013Q3($0.05)($0.05)ViewN/AView Earnings Details
8/14/2013Q2 2013($0.07)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.05)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.02)$1.93 million$0.67 millionViewN/AView Earnings Details
11/14/2012Q312($0.05)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.55)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.23)ViewN/AView Earnings Details
3/9/2012Q4 2011$0.06ViewN/AView Earnings Details
11/14/2011Q3 2011($0.13)ViewN/AView Earnings Details
8/15/2011Q2 2011($0.17)ViewN/AView Earnings Details
5/16/2011Q1 2011($0.25)ViewN/AView Earnings Details
3/30/2011Q4 2010$0.07ViewN/AView Earnings Details
11/12/2010Q3 2010($0.24)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.26)ViewN/AView Earnings Details
5/18/2010Q1 2010($0.25)ViewN/AView Earnings Details
3/29/2010Q4 2009($0.29)ViewN/AView Earnings Details
11/16/2009Q3 2009$0.01ViewN/AView Earnings Details
8/6/2009Q2 2009($0.40)ViewN/AView Earnings Details
5/6/2009Q1 2009($0.44)ViewN/AView Earnings Details
3/12/2009Q4 2008($0.35)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.43)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.98)ViewN/AView Earnings Details
5/2/2008Q1 2008($1.08)ViewN/AView Earnings Details
3/6/2008Q4 2007($0.53)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

CASI Pharmaceuticals (NASDAQ:CASI) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.13 EPS
Next Year EPS Consensus Estimate: $-0.13 EPS

Dividends

Dividend History for CASI Pharmaceuticals (NASDAQ:CASI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

CASI Pharmaceuticals (NASDAQ CASI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 24.52%
Institutional Ownership Percentage: 3.67%
Insider Trades by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)
Insider Trades by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)

CASI Pharmaceuticals (NASDAQ CASI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/22/2017Spectrum Pharmaceuticals IncMajor ShareholderBuy1,519,096$0.01$15,190.966,897,413View SEC Filing  
10/10/2017Wei-Wu HeDirectorBuy100,000$1.95$195,000.00View SEC Filing  
10/6/2017Wei-Wu HeDirectorBuy200,000$1.83$366,000.00View SEC Filing  
9/19/2017Wei-Wu HeDirectorBuy207,502$1.75$363,128.50513,525View SEC Filing  
9/18/2017Wei-Wu HeDirectorBuy173,500$1.75$303,625.00513,525View SEC Filing  
9/15/2017Wei-Wu HeDirectorBuy315,327$1.33$419,384.91212,323View SEC Filing  
10/28/2016Spectrum Pharmaceuticals IncMajor ShareholderBuy1,789,062$0.01$17,890.625,695,242View SEC Filing  
10/3/2016Wei-Wu HeDirectorBuy1,871,605$1.19$2,227,209.9524,698View SEC Filing  
6/24/2016Byte Ltd SparkleMajor ShareholderBuy3,753,855$1.19$4,467,087.45View SEC Filing  
3/7/2016China Growth Fund Idg-Accel IIMajor ShareholderBuy972,708$2.40$2,334,499.20View SEC Filing  
1/19/2016Cynthia W. HuCOOBuy16,800$0.72$12,096.0017,785View SEC Filing  
1/19/2016Ken RenCEOBuy15,000$0.73$10,950.0015,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

CASI Pharmaceuticals (NASDAQ CASI) News Headlines

Source:
DateHeadline
FY2017 EPS Estimates for CASI Pharmaceuticals, Inc. (CASI) Increased by AnalystFY2017 EPS Estimates for CASI Pharmaceuticals, Inc. (CASI) Increased by Analyst
www.americanbankingnews.com - January 8 at 2:56 AM
Spectrum Pharmaceuticals Inc Buys 1,519,096 Shares of CASI Pharmaceuticals, Inc. (CASI) StockSpectrum Pharmaceuticals Inc Buys 1,519,096 Shares of CASI Pharmaceuticals, Inc. (CASI) Stock
www.americanbankingnews.com - December 22 at 6:14 PM
Free Research Reports on these Biotech Stocks -- Vericel, ZIOPHARM Oncology, Cerecor, and CASI Pharma - PR Newswire (press release)Free Research Reports on these Biotech Stocks -- Vericel, ZIOPHARM Oncology, Cerecor, and CASI Pharma - PR Newswire (press release)
www.prnewswire.com - December 19 at 4:58 PM
Mid-Morning Market Update: Markets Open Higher; VeriFone Issues Weak Outlook - NasdaqMid-Morning Market Update: Markets Open Higher; VeriFone Issues Weak Outlook - Nasdaq
www.nasdaq.com - December 13 at 5:09 PM
CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer SymposiumTM (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)CASI Pharmaceuticals Announces Poster Presentation At The 2017 San Antonio Breast Cancer SymposiumTM (SABCS) On ENMD-2076 In Patients With Triple-Negative Breast Cancer (TNBC)
finance.yahoo.com - December 1 at 5:10 PM
 CASI Pharmaceuticals, Inc. (CASI) Given $3.50 Consensus Price Target by Brokerages CASI Pharmaceuticals, Inc. (CASI) Given $3.50 Consensus Price Target by Brokerages
www.americanbankingnews.com - November 23 at 1:28 PM
CASI Pharmaceuticals, Inc. (CASI) Posts Quarterly  Earnings Results, Beats Expectations By $0.01 EPSCASI Pharmaceuticals, Inc. (CASI) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 15 at 1:05 PM
CASI Pharmaceuticals Reports Third Quarter 2017 Financial ResultsCASI Pharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 5:27 PM
CASI Pharmaceuticals (CASI) Buy Rating Reiterated at Maxim GroupCASI Pharmaceuticals' (CASI) Buy Rating Reiterated at Maxim Group
www.americanbankingnews.com - November 14 at 4:40 PM
CASI Pharmaceuticals, Inc. (CASI) Scheduled to Post Quarterly Earnings on MondayCASI Pharmaceuticals, Inc. (CASI) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - November 6 at 5:22 AM
CASI Pharmaceuticals (CASI) vs. Brainstorm Cell Therapeutics (BCLI) Head to Head ComparisonCASI Pharmaceuticals (CASI) vs. Brainstorm Cell Therapeutics (BCLI) Head to Head Comparison
www.americanbankingnews.com - November 5 at 9:12 PM
-$0.04 EPS Expected for CASI Pharmaceuticals, Inc. (CASI) This Quarter-$0.04 EPS Expected for CASI Pharmaceuticals, Inc. (CASI) This Quarter
www.americanbankingnews.com - November 1 at 9:16 PM
Analyzing CASI Pharmaceuticals (CASI) and Adamas Pharmaceuticals (ADMS)Analyzing CASI Pharmaceuticals (CASI) and Adamas Pharmaceuticals (ADMS)
www.americanbankingnews.com - November 1 at 5:12 PM
CASI Pharmaceuticals, Capital Raise, Analysts Review, Product Development, and GuidanceCASI Pharmaceuticals, Capital Raise, Analysts Review, Product Development, and Guidance
finance.yahoo.com - October 31 at 6:07 PM
Reviewing CASI Pharmaceuticals (CASI) & The CompetitionReviewing CASI Pharmaceuticals (CASI) & The Competition
www.americanbankingnews.com - October 21 at 2:24 AM
CASI Pharma (CASI) Announces 7.95M Share Registed Direct Offering at $3/ShCASI Pharma (CASI) Announces 7.95M Share Registed Direct Offering at $3/Sh
www.streetinsider.com - October 14 at 4:43 PM
CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders - PR Newswire (press release)CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders - PR Newswire (press release)
www.prnewswire.com - October 14 at 3:37 AM
CASI Pharmaceuticals Reaches Analyst Target PriceCASI Pharmaceuticals Reaches Analyst Target Price
www.thestreet.com - October 13 at 5:37 PM
CASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing ShareholdersCASI Pharmaceuticals Announces $23.8 Million Registered Direct Offering Led By Existing Shareholders
finance.yahoo.com - October 13 at 5:37 PM
Insider Buying: CASI Pharmaceuticals, Inc. (CASI) Director Purchases 100,000 Shares of StockInsider Buying: CASI Pharmaceuticals, Inc. (CASI) Director Purchases 100,000 Shares of Stock
www.americanbankingnews.com - October 11 at 7:50 PM
CASI Pharmaceuticals, Inc. (CASI) Director Acquires $366,000.00 in StockCASI Pharmaceuticals, Inc. (CASI) Director Acquires $366,000.00 in Stock
www.americanbankingnews.com - October 10 at 7:38 PM
Head-To-Head Review: CASI Pharmaceuticals (CASI) & Its RivalsHead-To-Head Review: CASI Pharmaceuticals (CASI) & Its Rivals
www.americanbankingnews.com - September 25 at 2:20 AM
CASI Pharmaceuticals, Inc. (CASI) Expected to Announce Earnings of -$0.04 Per ShareCASI Pharmaceuticals, Inc. (CASI) Expected to Announce Earnings of -$0.04 Per Share
www.americanbankingnews.com - September 25 at 2:16 AM
Insider Buying: CASI Pharmaceuticals, Inc. (CASI) Director Purchases 173,500 Shares of StockInsider Buying: CASI Pharmaceuticals, Inc. (CASI) Director Purchases 173,500 Shares of Stock
www.americanbankingnews.com - September 20 at 8:24 PM
CASI Pharmaceuticals, Inc. (CASI) Director Wei-Wu He Purchases 207,502 SharesCASI Pharmaceuticals, Inc. (CASI) Director Wei-Wu He Purchases 207,502 Shares
www.americanbankingnews.com - September 20 at 8:22 PM
CASI Pharmaceuticals, Inc. (CASI) Director Buys $419,384.91 in StockCASI Pharmaceuticals, Inc. (CASI) Director Buys $419,384.91 in Stock
www.americanbankingnews.com - September 18 at 7:22 PM
HC Wainwright Reaffirms Buy Rating for CASI Pharmaceuticals, Inc. (CASI)HC Wainwright Reaffirms Buy Rating for CASI Pharmaceuticals, Inc. (CASI)
www.americanbankingnews.com - September 8 at 6:44 PM
BRIEF-CASI provides pipeline development updateBRIEF-CASI provides pipeline development update
www.reuters.com - September 7 at 4:41 PM
CASI Provides Pipeline Development UpdateCASI Provides Pipeline Development Update
finance.yahoo.com - September 7 at 4:41 PM
CASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global Investment ConferenceCASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 6 at 4:58 PM
CASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global Investment ConferenceCASI Pharmaceuticals To Present At The Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 6 at 4:58 PM
CASI Pharmaceuticals, Inc. (CASI) Issues Quarterly  Earnings ResultsCASI Pharmaceuticals, Inc. (CASI) Issues Quarterly Earnings Results
www.americanbankingnews.com - August 15 at 9:41 AM
CASI Pharmaceuticals Reports Second Quarter 2017 Financial ResultsCASI Pharmaceuticals Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 14 at 5:23 PM
Maxim Group Analysts Give CASI Pharmaceuticals, Inc. (CASI) a $4.00 Price TargetMaxim Group Analysts Give CASI Pharmaceuticals, Inc. (CASI) a $4.00 Price Target
www.americanbankingnews.com - August 14 at 1:06 PM
CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Scheduled to Post Earnings on MondayCASI Pharmaceuticals, Inc. (NASDAQ:CASI) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - August 7 at 7:50 AM
Brokers Issue Forecasts for CASI Pharmaceuticals, Inc.s Q2 2017 Earnings (NASDAQ:CASI)Brokers Issue Forecasts for CASI Pharmaceuticals, Inc.'s Q2 2017 Earnings (NASDAQ:CASI)
www.americanbankingnews.com - July 17 at 8:10 AM
CASI Pharmaceuticals, Inc. Expected to Earn Q3 2017 Earnings of ($0.04) Per Share (NASDAQ:CASI)CASI Pharmaceuticals, Inc. Expected to Earn Q3 2017 Earnings of ($0.04) Per Share (NASDAQ:CASI)
www.americanbankingnews.com - July 14 at 9:48 AM
BRIEF-Casi Pharmaceuticals reports Q1 loss per share $0.03BRIEF-Casi Pharmaceuticals reports Q1 loss per share $0.03
www.reuters.com - May 15 at 3:48 PM
CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial ConditionCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 31 at 4:18 PM
CASI Pharmaceuticals Announces Poster Presentations At AACR ... - PR Newswire (press release)CASI Pharmaceuticals Announces Poster Presentations At AACR ... - PR Newswire (press release)
www.prnewswire.com - March 29 at 12:29 PM
Ken Keyong Ren M.D., Ph.D.Ken Keyong Ren M.D., Ph.D.
www.bloomberg.com - January 5 at 9:33 PM
BRIEF-Casi Pharmaceuticals Inc entered into amendment with Talon TherapeuticsBRIEF-Casi Pharmaceuticals Inc entered into amendment with Talon Therapeutics
www.reuters.com - December 17 at 9:20 PM
CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ECASI PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E
biz.yahoo.com - December 16 at 9:34 PM
7:25 am CASI Pharma announces that Chinas FDA has accepted for review the Companys import drug registration application for EVOMELA for Injection7:25 am CASI Pharma announces that China's FDA has accepted for review the Company's import drug registration application for EVOMELA for Injection
us.rd.yahoo.com - December 5 at 4:56 PM
CASI Pharmas (CASI) Registration App for EVOMELA Accepted by Chinas FDACASI Pharma's (CASI) Registration App for EVOMELA Accepted by China's FDA
www.streetinsider.com - December 5 at 12:30 PM
BRIEF-Casi Pharmaceuticals reports third quarter 2016 resultsBRIEF-Casi Pharmaceuticals reports third quarter 2016 results
www.reuters.com - November 15 at 4:20 PM
CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of EquitCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equit
biz.yahoo.com - October 25 at 9:20 PM
BRIEF-Casi Pharmaceuticals Q2 loss per share $0.08BRIEF-Casi Pharmaceuticals Q2 loss per share $0.08
www.reuters.com - August 16 at 10:35 AM
CASI Pharma (CASI) Reports ENMD-2076 Phase 2 Met Stage 1 Endpoint in FLCCASI Pharma (CASI) Reports ENMD-2076 Phase 2 Met Stage 1 Endpoint in FLC
www.streetinsider.com - August 16 at 10:35 AM
CASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anCASI PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
biz.yahoo.com - August 15 at 11:19 AM

SEC Filings

CASI Pharmaceuticals (NASDAQ:CASI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

CASI Pharmaceuticals (NASDAQ:CASI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

CASI Pharmaceuticals (NASDAQ CASI) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.